Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Funao Su is a brand name for Brain Protein Hydrolysate Injection, a neurotrophic biologic developed and manufactured by Jiangsu Suzhong Pharmaceutical Group. Derived from porcine brain tissue, it consists of a complex mixture of low-molecular-weight peptides and free amino acids capable of crossing the blood-brain barrier. The drug exerts neuroprotective and neuroreparative effects by promoting neuronal protein synthesis, improving cerebral energy metabolism, and protecting neurons against hypoxia and toxic insults. It is primarily used in China for the treatment of ischemic stroke (cerebral infarction), traumatic brain injury, and cognitive impairment following cerebrovascular accidents. Clinical studies, such as CTR20150799, have evaluated its safety and pharmacokinetics in healthy volunteers to support further clinical development and regulatory compliance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on brain protein hydrolysate.